You are leaving our website

or Decline

Hardman & Co Issues Research Report on Alliance Pharma


("Alliance" or the "Group")

Set for resumption in growth: Alliance Pharma released a solid set of full year numbers, demonstrating the resilience of its underlying core businesses. As the company emerges from the loss of its toxicology product the business appears ready to resume growth with FY 14 underlying pre-tax profit growth having been 15%. The 2015 acquisition of MacuVision provides an additional franchise upon which to build. Coupled with a robust balance sheet and the capacity to fund quite significant opportunities, the outlook for growth looks better than it has done for 3 years.

To contact us:

Hardman & Co
11/12 Tokenhouse Yard


Mark Brewer
Martin Hall
Telephone: +44 20 7929 3399
Follow us on Twitter: @HardmanandCo

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.